Latest News & Features
Americas
Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this. 30 April 2013
Americas
James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin. 30 April 2013
Americas
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges. 30 April 2013
Americas
Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP. 29 April 2013
Asia
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics. 25 April 2013
Americas
The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements. 24 April 2013
Americas
Japanese pharma Shionogi has brought a lawsuit against Hospira Inc to keep it from marketing a generic version of Shionogi’s Doribax, alleging it infringes one of the company’s patents. 19 April 2013
Big Pharma
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat. 19 April 2013
Americas
Swiss pharmaceutical firm Novartis has filed a lawsuit against Accord Healthcare, Fresenius Kabi and Hikma Farmaceutica for applying to market generic versions of its cancer drug Zometa. 17 April 2013
Americas
The US Supreme Court has heard oral arguments on whether genetic material is patent eligible subject matter. Jennifer Camacho, shareholder at Greenberg Traurig, reports on Monday's proceedings. 16 April 2013